• Above all, we make a difference.
  • Risk Factors & Risk Reduction References

      

    1. Fletcher SW. Risk prediction models for breast cancer screening. In: UpToDate. Hayes DF, Sokol HN (eds.). Waltham, MA: UpToDate, 2013.
    2. National Cancer Institute. Breast Cancer Risk Assessment Tool. http://www.cancer.gov/bcrisktool/Default.aspx, 2011.
    3. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER Fast Stats, 2000-2010. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, 2013.
    4. American Cancer Society. Breast Cancer Facts & Figures, 2013-2014, 2013.
    5. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER Cancer Statistics Review, 1975-2010. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, 2013.
    6. Willett WC, Tamimi RM, Hankinson SE, Hunter DJ, Colditz GA. Chapter 20: Nongenetic Factors in the Causation of Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
    7. Ewertz M, Duffy SW, Adami HO, et al. Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer. 46(4):597-603, 1990.
    8. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth. N Engl J Med. 331(1):5-9, 1994.
    9. Rosner B, Colditz GA and Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 139: 819-835, 1994.
    10. Colditz GA and Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 152: 950-64, 2000.
    11. Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 156(9):635-48, 2012.
    12. Shinde SS, Forman MR, Kuerer HM, et al. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer. 116(21):4933-43, 2010.
    13. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 13(11):1141-51, 2012.
    14. Harris JR, Lippman ME, Veronesi U and Willett W. Breast cancer (1). N Engl J Med. 327:319-28, 1992.
    15. Kelsey JL and Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health. 17:47-67, 1996.
    16. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 8(4):R43, 2006.
    17. Reeves GK, Pirie K, Green J, et al. for the Million Women Study Collaborators. Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. Br J Cancer. 100(3):538-44, 2009.
    18. Key T, Appleby P, Barnes I, Reeves G for the Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 94(8): 606-616, 2002.
    19. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 350: 1047-59, 1997.
    20. Lacey JV, Jr., Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 288:334-41, 2002.
    21. Kwan ML, Kushi LH, Weltzien E, et al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study. J Clin Oncol. 28(29):4410-6, 2010.
    22. Newcomb PA, Kampman E, Trentham-Dietz A, et al. Alcohol consumption before and after breast cancer diagnosis: associations with survival from breast cancer, cardiovascular disease, and other causes. J Clin Oncol. 31(16):1939-46, 2013.
    23. Flatt SW, Thomson CA, Gold EB, et al. Low to moderate alcohol intake is not associated with increased mortality after breast cancer. Cancer Epidemiol Biomarkers Prev. 19(3):681-8, 2010.
    24. Gou YJ, Xie DX, Yang KH, et al. Alcohol consumption and breast cancer survival: a meta- analysis of cohort studies. Asian Pac J Cancer Prev. 14(8):4785-4790, 2013.
    25. Egan KM, Newcomb PA, Longnecker MP, et al. Jewish religion and risk of breast cancer. Lancet. 347: 1645-6, 1996.
    26. National Cancer Institute. Genetics of breast and ovarian cancer (PDQ). http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page2, 2013.
    27. Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 66(16):8297-308, 2006.
    28. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336: 1401-8, 1997.
    29. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 25(11):1329-33, 2007.
    30. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 98(8):1457-66, 2008.
    31. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 347:1713-27, 1996.
    32. Hankinson SE, Colditz GA, Manson JE, et al. A prospective study of oral contraceptive use and risk of breast cancer. Cancer Causes Control. 8:65-72, 1997.
    33. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev. 11(11):1375-81, 2002.
    34. Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev. 19(10):2496-502, 2010.
    35. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 346:2025-32, 2002.
    36. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ. 335(7621):651, 2007.
    37. Beral V, Doll R, Hermon C, et al. for the Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 371(9609):303-14, 2008.
    38. Bigrigg A, Evans M, Gbolade B, et al. Depo Provera. Position paper on clinical use, effectiveness and side effects. Br J Fam Plann. 25(2):69-76, 1999.
    39. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra). J Fam Plann Reprod Health Care. 30(1):43-5, 2004.
    40. Skegg DC, Noonan EA, Paul C, et al. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. JAMA. 273(10):799-804, 1995.
    41. Li CI, Beaber EF, Chen Tang MT, Porter PL, Daling JR, Malone KE. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res. 72(8):2028-35, 2012.
    42. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 12(4):1071-82, 2005.
    43. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer. 90(1):153-9, 2004.
    44. Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat. 137(3):883-92, 2013.
    45. Endogenous Hormones and Breast Cancer Collaborative Group. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol. 14(10):1009-19, 2013.
    46. Key TJ, Appleby PN, Reeves GK, et al. for the Endogenous Hormones and Breast Cancer Collaborative Group. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 105(5):709-22, 2011.
    47. Cauley JA, Lucas FL, Kuller LH, et al. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA. 276: 1404-8, 1996.
    48. Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med. 336:611-7, 1997.
    49. Zmuda JM, Cauley JA, Ljung BM, et al. Bone mass and breast cancer risk in older women: differences by stage at diagnosis. J Natl Cancer Inst. 336: 611-7, 2001.
    50. Chen Z, Arendell L, Aickin M, Cauley J, Lewis CE, Chlebowski R for the Women's Health Initiative Program, National Heart, Lung and Blood Institute, US Department of Health and Human Services. Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. Cancer. 113(5):907-15, 2008.
    51. Grenier D, Cooke AL, Lix L, Metge C, Lu H, Leslie WD. Bone mineral density and risk of postmenopausal breast cancer. Breast Cancer Res Treat. 126(3):679-86, 2011.
    52. Qu X, Zhang X, Qin A, et al. Bone mineral density and risk of breast cancer in postmenopausal women. Breast Cancer Res Treat. 138(1):261-71, 2013.
    53. Kerlikowske K, Shepherd J, Creasman J, Tice JA, Ziv E, Cummings SR. Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst. 97(5):368-74, 2005.
    54. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 356(3):227-36, 2007.
    55. Yaghjyan L, Colditz GA, Collins LC, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst. 103(15):1179-89, 2011.
    56. Pisano ED, Gatsonis C, Hendrick E, et al. for the Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 27;353(17):1773-83, 2005.
    57. Bernier MO, Plu-Bureau G, Bossard N, et al. Breastfeeding and risk of breast cancer: a meta-analysis of published studies. Hum Reprod Update. 6:374-86, 2000.
    58. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breast feeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet 20:187-95, 2002.
    59. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 19;8(4):R43, 2006.
    60. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 171(1):45-53, 2010.
    61. U.S. Department of Health and Human Services Office on Women’s Health. Breastfeeding. http://www.womenshealth.gov/breastfeeding/why-breastfeeding-is-important/, 2010.
    62. Tehard B, Friedenreich CM, Oppert JM, Clavel-Chapelon. Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev. 15(1):57-64, 2006.
    63. Eliassen AH, Hankinson SE, Rosner B, Holmes MD, Willett WC. Physical activity and risk of breast cancer among postmenopausal women. Arch Intern Med. 170(19):1758-64, 2010.
    64. Wu Y, Zhang D, Kang S. Physical activity and risk of breast cancer: a meta-analysis of prospective studies. Breast Cancer Res Treat. 137(3):869-82, 2013.
    65. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 278: 1407-11, 1997.
    66. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 152:514-27, 2000.
    67. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 335(7630):1134, 2007.
    68. McTiernan A, Wu L, Chen C, et al. for the Women's Health Initiative Investigators. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity (Silver Spring). 14(9):1662-77, 2006.
    69. Friedenreich CM, Woolcott CG, McTiernan A, et al. Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. J Clin Oncol. 28(9):1458-66, 2010.
    70. Smith AJ, Phipps WR, Thomas W, Schmitz KH, Kurzer MS. The effects of aerobic exercise on estrogen metabolism in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev. 22:756-764, 2013.
    71. Rogers CJ, Colbert LH, Greiner JW, Perkins SN, Hursting SD. Physical activity and cancer prevention: pathways and targets for intervention. Sports Med. 38(4):271-96, 2008.
    72. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 293(20):2479-86, 2005.
    73. Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 17(2):379-86, 2008.
    74. Irwin ML, McTiernan A, Manson JE, et al. Physical activity and survival in postmenopausal women with breast cancer: results from the Women's Health Initiative. Cancer Prev Res (Phila). 4(4):522-9, 2011.
    75. Ibrahim EM, Al-Homaidh A. Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol. 28(3):753-65, 2011.
    76. Beasley JM, Kwan ML, Chen WY, et al. Meeting the physical activity guidelines and survival after breast cancer: findings from the after breast cancer pooling project. Breast Cancer Res Treat. 131(2):637-43, 2012.
    77. Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol. 25(17):2345-51, 2007.
    78. Chen X, Lu W, Zheng W, et al. Exercise after diagnosis of breast cancer in association with survival. Cancer Prev Res (Phila). 4(9):1409-18, 2011.
    79. Mutrie N, Campbell AM, Whyte F, et al. Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial. BMJ. 334(7592):517, 2007.
    80. Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R, Roalfe A. Randomized trial of exercise therapy in women treated for breast cancer. J Clin Oncol. 25(13):1713-21, 2007.
    81. Alfano CM, Smith AW, Irwin ML, et al. Physical activity, long-term symptoms, and physical health-related quality of life among breast cancer survivors: a prospective analysis. J Cancer Surviv. 1(2):116-28, 2007.
    82. Penttinen HM, Saarto T, Kellokumpu-Lehtinen P, et al. Quality of life and physical performance and activity of breast cancer patients after adjuvant treatments. Psychooncology. 20(11):1211-20, 2011.
    83. Kushi LH, Doyle C, McCullough M, et al. for the American Cancer Society 2010 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 62(1):30-67, 2012.
    84. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 358: 1389-99, 2001.
    85. Pharoah PDP, Day NE, Duggy S, Easton DF, Ponder BAJ. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 71(5):800-9, 1997.
    86. Anderson DE and Badzioch MD. Familial breast cancer risks. Effects of prostate and other cancers. Cancer. 72: 114-9, 1993.
    87. Anderson DE and Badzioch MD. Familial effects of prostate and other cancers on lifetime breast cancer risk. Breast Cancer Res Treat. 28: 107-13, 1993.
    88. Valeri A, Fournier G, Morin V, et al. Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. Int J Cancer. 86: 883-7, 2000.
    89. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Breast cancer screening and diagnosis. V.1.2012. http://www.nccn.org, 2011.
    90. American Cancer Society. American Cancer Society recommendations for early breast cancer detection in women without breast symptoms.
      http://www.cancer.org/Cancer/BreastCancer/MoreInformation/BreastCancerEarlyDetection/breast-cancer-early-detection-acs-recs, 2013.
    91. Zhang S, Hunter DJ, Forman MR, et al. Dietary carotenoids, and vitamins A, C, and E and risk of breast cancer. J Natl Cancer Inst. 91:547-556, 1999.
    92. van Gils CH, Peeters PHM, Bueno-de-Mesquita HB, et al. Consumption of vegetables and fruits and risk of breast cancer. JAMA. 293(2):183-93, 2005.
    93. Boggs DA, Palmer JR, Wise LA, et al. Fruit and vegetable intake in relation to risk of breast cancer in the Black Women's Health Study. Am J Epidemiol. 172(11):1268-79, 2010.
    94. Aune D, Chan DS, Vieira AR, et al. Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat. 134(2):479-93, 2012.
    95. Jung S, Spiegelman D, Baglietto L, et al. Fruit and vegetable intake and risk of breast cancer by hormone receptor status. J Natl Cancer Inst. 105(3):219-36, 2013.
    96. Eliassen AH, Hendrickson SJ, Brinton LA, et al. Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies. J Natl Cancer Inst. 104(24):1905-16, 2012.
    97. Cui Y, Shikany JM, Liu S, Shagufta Y, Rohan TE. Selected antioxidants and risk of hormone receptor-defined invasive breast cancers among postmenopausal women in the Women's Health Initiative Observational Study. Am J Clin Nutr. 87(4):1009-18, 2008.
    98. Kabat GC, Kim M, Adams-Campbell LL, et al. for the Women’s Health Initiative Investigators. Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women. Am J Clin Nutr. 90(1):162-9, 2009.
    99. Nagel G, Linseisen J, van Gils CH, et al. Dietary beta-carotene, vitamin C and E intake and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Breast Cancer Res Treat. 119(3):753-65, 2010.
    100. Maillard V, Kuriki K, Lefebvre B, et al. Serum carotenoid, tocopherol and retinol concentrations and breast cancer risk in the E3N-EPIC study. Int J Cancer. 127(5):1188-96, 2010.
    101. Zhang X, Spiegelman D, Baglietto L, et al. Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies. Am J Clin Nutr. 95(3):713-25, 2012.
    102. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 330:1029 –35, 1994.
    103. Omenn GS, Goodman G, Thornquist M, et al. Chemoprevention of lung cancer: the beta-Carotene and Retinol Efficacy Trial (CARET) in high-risk smokers and asbestos-exposed workers. IARC Sci Publ: 67-85, 1996.
    104. Druesne-Pecollo N, Latino-Martel P, Norat T, et al. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer. 127(1):172-84, 2010.
    105. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V; for the Million Women Study collaborators. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 12(8):785-94, 2011.
    106. Mellemkjær L, Christensen J, Frederiksen K, et al. Leg length, sitting height and postmenopausal breast cancer risk. Br J Cancer. 107(1):165-8, 2012.
    107. Kabat GC, Heo M, Kamensky V, Miller AB, Rohan TE. Adult height in relation to risk of cancer in a cohort of Canadian women. Int J Cancer. 132(5):1125-32, 2013.
    108. Kabat GC, Anderson ML, Heo M, et al. Adult stature and risk of cancer at different anatomic sites in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 22(8):1353-1363, 2013.
    109. Ritte R, Lukanova A, Tjønneland A, et al. Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study. Int J Cancer. 132(11):2619-29, 2013.
    110. Wang J, Costantino JP, Tan-Chiu E, et al. Lower-category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst. 96(8):616-20, 2004.
    111. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 353(3):229-37, 2005.
    112. Tice JA, O'Meara ES, Weaver DL, Vachon C, Ballard-Barbash R, Kerlikowske K. Benign breast disease, mammographic breast density, and the risk of breast cancer. J Natl Cancer Inst. 105(14):1043-1049, 2013.
    113. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 26(26):4282-8, 2008.
    114. Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi women. Breast Cancer Res Treat. 129(1):185-90, 2011.
    115. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 22(12):2328-35, 2004.
    116. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 27(35):5887-92, 2009.
    117. Malone KE, Begg CB, Haile RW, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 28(14):2404-10, 2010.
    118. van der Kolk DM, de Bock GH, Leegte BK, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat. 124(3):643-51, 2010.
    119. Isaacs C, Peshkin BN, Schwartz M. Chapter 19: Genetic Testing and Management of Patients with Hereditary Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
    120. Metcalfe K, Gershman S, Lynch HT et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 104(9):1384-92, 2011.
    121. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 367(9510):595-604, 2006.
    122. Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 106(10):1697-701, 2012.
    123. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 22(4):735-42, 2004.
    124. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 60(5): 1079–1084, 1997.
    125. American Cancer Society. Detailed guide on ovarian cancer. Do we know what causes ovarian cancer? http://www.cancer.org/Cancer/OvarianCancer/DetailedGuide/ovarian-cancer-what-causes. American Cancer Society, 2013.
    126. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 101(2):80-7, 2009.
    127. Jernström H, Lubinski J, Lynch HT, et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 96: 1094-8, 2004.
    128. Pijpe A, Manders P, Brohet RM, et al. for the Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON). Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat. 120(1):235-44, 2010.
    129. Jernström H, Lerman C, Ghadirian P, et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 354(9193):1846-50, 1999.
    130. Rebbeck TR, Wang Y, Kantoff PW, et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res. 61(14):5420-4, 2001.
    131. Cullinane CA, Lubinski J, Neuhausen SL, et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 117(6):988-91, 2005.
    132. Chang-Claude J, Andrieu N, Rookus M, et al. for the Epidemiological Study of Familial Breast Cancer (EMBRACE), Gene Etude Prospective Sein Ovaire (GENEPSO), Genen Omgeving studie van de werkgroep Hereditiair Borstkanker Onderzoek Nederland (GEO-HEBON) and International BRCA1/2 Carrier Cohort Study (IBCCS) collaborators group. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev. 16(4):740-6, 2007.
    133. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol. 25(25):3831-6, 2007.
    134. Narod SA, Dubé MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 94(23):1773-9, 2002.
    135. Milne RL, Osorio A, Ramón Y, et al. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 119(1):221-32, 2010.
    136. Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 46(12):2275-84, 2010.
    137. Feig SA. Adverse effects of screening mammography. Radiol Clin North Am. 42: 807-19, 2004.
    138. Berrington de Gonzalez A, Reeves G. Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits. Br J Cancer. 93:590-6, 2005.
    139. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. (4):CD001877, 2009.
    140. Pijpe A, Andrieu N, Easton DF, et al for GENEPSO; EMBRACE; HEBON. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ. 345:e5660, 2012.
    141. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst. 93(20):1563-8, 2001.
    142. Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work and risk of breast cancer. Epidemiology. 17(1):108-11, 2006.
    143. Jia Y, Lu Y, Wu K, et al. Does night work increase the risk of breast cancer? A systematic review and meta-analysis of epidemiological studies. Cancer Epidemiol. 37(3):197-206, 2013.
    144. Schernhammer ES, Berrino F, Krogh V,et al. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 100(12):898-905, 2008.
    145. Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev. 18(1):74-9, 2009.
    146. Kilbride KE and Newman LA. Chapter 25: Lobular Carcinoma In Situ: Clinical Management, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
    147. Bagaria SP, Shamonki J, Kinnaird M, Ray PS, Giuliano AE. The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma? Ann Surg Oncol. 18(7):1845-51, 2011.
    148. Shah-Khan MG, Geiger XJ, Reynolds C, Jakub JW, Deperi ER, Glazebrook KN. Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol. 19(10):3131-8, 2012.
    149. Andrade VP, Ostrovnaya I, Seshan VE, et al. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res. 14(4):R103, 2012.
    150. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Breast cancer risk reduction. V.1.2012. http://www.nccn.org, 2012.
    151. Vogel VG, Costantino JP, Wickerham DL, et al. for the National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res. 3(6):696-706, 2010.
    152. Goss PE, Ingle JN, Alés-Martínez JE, et al. for the NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 364(25):2381-91, 2011.
    153. U.S. Food and Drug Administration. Menopause and hormones. http://www.fda.gov/ForConsumers/ByAudience/ForWomen/ucm118624.htm, 2013.
    154. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332: 1589-93, 1995.
    155. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:485-91, 2000.
    156. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288(3):321-33, 2002.
    157. Beral V for the Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 362:419-27, 2003.
    158. Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 128(1):144-56, 2011.
    159. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 289:3243-53, 2003.
    160. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative Randomized Trials. JAMA. 310(13):1353-1368, 2013.
    161. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and risk of invasive breast cancer. Arch Intern Med. 166(9):1027-1032, 2006.
    162. Brinton LA, Richesson D, Leitzmann MF, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers P113-119]rev. 17(11):3150-60, 2008.
    163. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 345:e6409, 2012.
    164. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 103(3):250-63, 2011.
    165. White KK, Park SY, Kolonel LN, Henderson BE, Wilkens LR. Body size and breast cancer risk: The multiethnic cohort. Int J Cancer. 131(5):E705-16, 2012.
    166. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis. Int J Cancer. 124(3):698-712, 2009.
    167. Hvidtfeldt UA, Gunter MJ, Lange T, et al. Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. Cancer Epidemiol Biomarkers Prev. 21(7):1203-12, 2012.
    168. Michels KB, Solomon CG, Hu FB, et al. for the Nurses' Health Study. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care. 26(6):1752-8, 2003.
    169. Liao S, Li J, Wei W, et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev. 12(4):1061-5, 2011.
    170. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 121(4):856-62, 2007.
    171. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 300(23):2754-64, 2008.
    172. Del Giudice ME, Fantus IG, Ezzat S, et al. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat. 47:111-20, 1998.
    173. Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE. Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev. 16(1):161-4, 2007.
    174. Vrieling A, Buck K, Kaaks R, Chang-Claude J. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat. 123(3):641-9, 2010.
    175. Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA. 296(2):193-201, 2006.
    176. Ahn J, Schatzkin A, Lacey JV Jr, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 167(19):2091-102, 2007.
    177. Teras LR, Goodman M, Patel AV, Diver WR, Flanders WD, Feigelson HS. Weight loss and postmenopausal breast cancer in a prospective cohort of overweight and obese US women. Cancer Causes Control. 22(4):573-9, 2011.
    178. Michels KB, Terry KL, Eliassen AH, Hankinson SE, Willett WC. Adult weight change and incidence of premenopausal breast cancer. Int J Cancer. 130(4):902-9, 2012.
    179. Connolly BS, Barnett C, Vogt KN, et al. A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr Cancer. 44: 127-38, 2002.
    180. Harvie M, Hooper L and Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev. 4: 157-73, 2003.
    181. MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG. Body size and composition and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 13(12):2117-25, 2004.
    182. Han D, Nie J, Bonner MR, et al. Lifetime adult weight gain, central adiposity, and the risk of pre- and postmenopausal breast cancer in the Western New York exposures and breast cancer study. Int J Cancer.119(12):2931-7, 2006.
    183. Harris HR, Willett WC, Terry KL, Michels KB. Body fat distribution and risk of premenopausal breast cancer in the Nurses' Health Study II. J Natl Cancer Inst. 103(3):273-8, 2011.
    184. Gao X, Fisher SG, Bahman Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 56(4):1038-45, 2003.
    185. Trentham-Dietz A, Newcomb PA, Nichols HB, Hampton JM. Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res Treat. 105(2):195-207, 2007.
    186. Nsouli-Maktabi HH, Henson DE, Younes N, Young HA, Cleary SD. Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age. Breast Cancer Res Treat. 129(3):963-9, 2011.
    187. Simone NL, Dan T, Shih J, et al. Twenty-five year results of the national cancer institute randomized breast conservation trial. Breast Cancer Res Treat. 132(1):197-203, 2012.
    188. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 101(15):1058-65, 2009.
    189. Bessonova L, Taylor TH, Mehta RS, Zell JA, Anton-Culver H. Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer. Cancer Epidemiol Biomarkers Prev. 20(2):389-96, 2011.
    190. Saltzman BS, Malone KE, McDougall JA, Daling JR, Li CI. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res Treat. 135(3):849-55, 2012.
    191. Morrow M and Harris JR. Chapter 26: Ductal carcinoma in situ and microinvasive carcinoma, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition. Lippincott Williams and Wilkins, 2010.
    192. Innos K, Horn-Ross PL. Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 111(3):531-40, 2008.
    193. Falk RS, Hofvind S, Skaane P, Haldorsen T. Second events following ductal carcinoma in situ of the breast: a register-based cohort study. Breast Cancer Res Treat. 129(3):929-38, 2011.
    194. Kenney LB, Yasui Y, Inskip PD, et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med. 141(8):590-7, 2004.
    195. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 25(12):1489-97, 2007.
    196. Horwich A, Swerdlow AJ. Second primary breast cancer after Hodgkin's disease. Br J Cancer. 90(2):294-8, 2004.
    197. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 117(6):1806-16, 2011.
    198. Nissen MJ, Lazovich D and Jolitz G. Breast carcinoma after cancer at another site: method of detection, tumor characteristics, and surgical treatment. Cancer. 89: 1999-2005, 2000.
    199. Koivisto-Korander R, Scélo G, Ferro G, et al. Second primary malignancies among women with uterine sarcoma. Gynecol Oncol. 126(1):30-5, 2012.
    200. Song F, Qureshi AA, Giovannucci EL, et al. Risk of a second primary cancer after non-melanoma skin cancer in white men and women: a prospective cohort study. PLoS Med. 10(4):e1001433, 2013.
    201. Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 91(7):629-34, 1999.
    202. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 25(12):1482-8, 2007.
    203. Hancock SL, Tucker MA and Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 85: 25-31, 1993.
    204. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 290(4):465-75, 2003.
    205. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 21(23):4386-94, 2003.
    206. Guibout C, Adjadu E, Rubino C. et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol. 23(1):197-204, 2005.
    207. Swerdlow AJ, Cooke R, Bates A, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. J Clin Oncol. 30(22):2745-52, 2012.
    208. Yaffe MJ, Mainprize JG. Risk of radiation-induced breast cancer from mammographic screening. Radiology. 258(1):98-105, 2011.
    209. Zeeb H, Blettner M, Langner I, et al. Mortality from cancer and other causes among airline cabin attendants in Europe: a collaborative cohort study in eight countries. Am J Epidemiol. 158(1):35-46, 2003.
    210. Rushton L, Bagga S, Bevan R, et al. Occupation and cancer in Britain. Br J Cancer. 102(9):1428-37, 2010.
    211. Pukkala E, Helminen M, Haldorsen T, et al. Cancer incidence among Nordic airline cabin crew. Int J Cancer. 131(12):2886-97, 2012.
    212. Institute of Medicine (IOM). Breast cancer and the environment: A life course approach. The National Academies Press: Washington, D.C. http://www.iom.edu/Reports/2011/Breast-Cancer-and-the-Environment-A-Life-Course-Approach.aspx, 2012.
    213. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 16;97(6):439-48, 2005.
    214. Krieger N, Chen JT, Waterman PD. Decline in US breast cancer rates after the Women's Health Initiative: socioeconomic and racial/ethnic differentials. Am J Public Health. 100 Suppl 1:S132-9, 2010.
    215. Gilliland FD, Hunt WC, Baumgartner KB, et al. Reproductive risk factors for breast cancer in Hispanic and non-Hispanic white women: the New Mexico Women's Health Study. Am J Epidemiol.148(7):683-92, 1998.
    216. American Cancer Society. Cancer Facts & Figures for African Americans: 2013-2014, 2013.
    217. Warner ET, Tamimi RM, Boggs DA, et al. Estrogen receptor positive tumors: do reproductive factors explain differences in incidence between black and white women? Cancer Causes Control. 24(4):731-9, 2013.
    218. Haiman CA, Pike MC, Bernstein L, et al. Ethnic differences in ovulatory function in nulliparous women. Br J Cancer. 86:367-71, 2002.
    219. Wu T, Mendola P, Buck GM. Ethnic differences in the presence of secondary sex characteristics and menarche among US girls: the Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics. 110:752-7, 2002.
    220. Anderson SE, Dallal GE, Must A. Relative weight and race influence average age at menarche: results from two nationally representative surveys of US girls studied 25 years apart. Pediatrics. 111:844-50, 2003.
    221. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 295(21):2492-502, 2006.
    222. Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol. 14(10):2994-3003, 2007.
    223. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 109(1):123-139, 2008.
    224. Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL. Early onset of breast cancer in a group of British black women. Br J Cancer. 98(2):277-81, 2008.
    225. Lund MJ, Butler EN, Hair BY, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer. 116(11):2549-59, 2010.
    226. Stark A, Kleer CG, Martin I, et al. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer. 116(21):4926-32, 2010.
    227. Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 118(22):5463-72, 2012.
    228. Jones BA, Kasl SV, Howe CL, et al. African-American/White differences in breast carcinoma: p53 alteration and other tumor characteristics. Cancer. 101: 1293-1301, 2004.
    229. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 110(4):876-84, 2007.
    230. Shinde SS, Forman MR, Kuerer HM, et al. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer. 116(21):4933-43, 2010.
    231. Gaudet MM, Press MF, Haile RW, et al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. 130(2):587-97, 2011.
    232. Yost K, Perkins C, Cohen R, et al. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 12: 703-11, 2001.
    233. Braaten T, Weiderpass E, Kumle M, et al. Education and risk of breast cancer in the Norwegian-Swedish women's lifestyle and health cohort study. Int J Cancer. 110: 579-83, 2004.
    234. Braaten T, Weiderpass E, Kumle M, Lund E. Explaining the socioeconomic variation in cancer risk in the Norwegian Women and Cancer Study. Cancer Epidemiol Biomarkers Prev. 14(11 Pt 1):2591-7, 2005.
    235. Fujino Y, Mori M, Tamakoshi A, et al. for the JACC Study Group. A prospective study of educational background and breast cancer among Japanese women. Cancer Causes Control. 19(9):931-7, 2008.
    236. Keegan TH, John EM, Fish KM, Alfaro-Velcamp T, Clarke CA, Gomez SL. Breast cancer incidence patterns among California Hispanic women: differences by nativity and residence in an enclave. Cancer Epidemiol Biomarkers Prev. 19(5):1208-18, 2010.
    237. Larsen SB, Olsen A, Lynch J, et al. Socioeconomic position and lifestyle in relation to breast cancer incidence among postmenopausal women: a prospective cohort study, Denmark, 1993-2006. Cancer Epidemiol. 35(5):438-41, 2011.
    238. dos Santos Silva I and Beral V. Socioeconomic differences in reproductive behaviour. IARC Sci Publ: 285-308, 1997.
    239. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Food and Nutrition Board, Institute of Medicine. Ross CA, Taylor CL, Yaktine AL, Del Valle HB (eds.). Dietary reference intakes for calcium and vitamin D. The National Academies Press, National Academy of Sciences: Washington, D.C. http://www.iom.edu/vitaminD, 2010.
    240. Bolton KL, Chenevix-Trench G, Goh C, et al for the EMBRACE, kConFab Investigators and Cancer Genome Atlas Research Network. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 307(4):382-90, 2012.
    241. Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 306(14):1557-65, 2011.
    242. Lesnock JL, Darcy KM, Tian C, et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer. 108(6):1231-7, 2013,
    243. McLaughlin JR, Rosen B, Moody J, et al. J Natl Cancer Inst. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.105(2):141-8, 2013.
    244. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment: Breast and ovarian, Version 1.2012, 2012.
    245. Schrag D, Kuntz KM, Garber JE and Weeks JC. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 336:1465-71, 1997.
    246. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 340:77-84, 1999.
    247. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 93:1633-7, 2001.
    248. Calderon-Margalit R, Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer. 112(3):357-64, 2004.
    249. Geiger Am, Yu O, Herrinton LJ, et al. A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices. Arch Intern Med. 165(5):516-20, 2005.
    250. Kaas R, Verhoef S, Wesseling J, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg. 251(3):488-92, 2010.
    251. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. (11):CD002748, 2010.
    252. Grann VR, Jacobson JS, Thomason D, et al. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol. 20:2520-9, 2002.
    253. van Roosmalen MS, Verhoef LC, Stalmeier PF, et al. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J Clin Oncol. 20:2092-100, 2002.
    254. Sigal BM, Munoz DF, Kurian AW, Plevritis SK. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 21(7):1066-77, 2012.
    255. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 346:1609-15, 2002.
    256. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346:1616-22, 2002.
    257. Finch A, Beiner M, Lubinski J, et al. for the Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 296(2):185-92, 2006.
    258. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 26(8):1331-7, 2008.
    259. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 101(2):80-7, 2009.
    260. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 304(9):967-975, 2010.
    261. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 28:222-231, 2010.
    262. Kotsopoulos J, Lubinski J, Lynch HT, et al. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 21(7):1089-96, 2012.
    263. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 97(22):1652-62, 2005.
    264. Cuzick J, Forbes JF, Sestak I, et al. for the International Breast Cancer Intervention Study I (IBIS-I) Investigators. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 21;99(4):272-82, 2007.
    265. Veronesi U, Maisonneuve P, Rotmensz N, et al. for the Italian Tamoxifen Study Group. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 99(9):727-37, 2007.
    266. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 65:125-34, 2001.
    267. Martino S, Cauley JA, Barrett-Connor E, et al. for the CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 96(23):1751-1761, 2004.
    268. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 355(2):125-37, 2006.
    269. Cuzick J, Sestak I, Bonanni B, et al. for the SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 381(9880):1827-34, 2013.
    270. Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 158(8):604-14, 2013.
    271. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 101(1):113-21, 2007.
    272. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 356:1876-81, 2000.
    273. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 286:2251-6, 2001.
    274. Mavaddat N, Barrowdale D, Andrulis IL, et al. for the Consortium of Investigators of Modifiers of BRCA1/2. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 21(1):134-47, 2012.
    275. Gronwald J, Tung N, Foulkes WD, et al. for the Hereditary Breast Cancer Clinical Study Group. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer.118(9):2281-4, 2006.
    276. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 91(21):1829-46, 1999.
    277. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 95(7):526-32, 2003.
    278. Jakesz R, Jonat W, Gnant M, et al. on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG) and the German Adjuvant Breast Cancer Group (GABG). Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 366(9484):455-62, 2005.
    279. Forbes JF, Cuzick J, Budzar A, Howell A, Tobias JS, Baum M for the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9(1):45-53, 2008.
    280. Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 26(12):1956-64, 2008.
    281. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 26(7):1051-7, 2008.
    282. Frost MH, Schaid DJ, Sellers TA, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA. 284:319-24, 2000.
    283. Barton MB, West CN, Liu IL, et al. Complications following bilateral prophylactic mastectomy. J Natl Cancer Inst Monogr. (35):61-6, 2005.
    284. Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol. 26(24):3943-9, 2008.
    285. Fabian CJ, Kimler BF, Zalles CM, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst. 92:1217-27, 2000.
    286. Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 93:624-32, 2001.
    287. Kurian AW, Mills MA, Jaffee M, et al. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Cancer Epidemiol Biomarkers Prev. 14(5):1082-9, 2005.
    288. Higgins SA, Matloff ET, Rimm DL, et al. Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer. Breast Cancer Res. 7(6):R1017-22, 2005.
    289. Euhus DM, Bu D, Milchgrub S, et al. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 17(5):1051-9, 2008.
    290. Ibarra-Drendall C, Wilke LG, Zalles C, et al. Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study. Cancer Epidemiol Biomarkers Prev. 18(5):1379-85, 2009.
    291. Loud JT, Beckjord EB, Nichols K, Peters J, Giusti R, Greene MH. Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer. BMC Womens Health. 9:20, 2009.
    292. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 28(22):3582-90, 2010.
    293. Cummings SR, Ensrud K, Delmas PD, et al. for the PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 362(8):686-96, 2010.
    294. Larsson SC, Akesson A, Wolk A. Long-term dietary acrylamide intake and breast cancer risk in a prospective cohort of Swedish women. Am J Epidemiol. 169(3):376-81, 2009.
    295. Wilson KM, Mucci LA, Cho E, Hunter DJ, Chen WY, Willett WC. Dietary acrylamide intake and risk of premenopausal breast cancer. Am J Epidemiol. 169(8):954-61, 2009.
    296. Wilson KM, Mucci LA, Rosner BA, Willett WC. A prospective study on dietary acrylamide intake and the risk for breast, endometrial, and ovarian cancers. Cancer Epidemiol Biomarkers Prev. 19(10):2503-15, 2010.
    297. Burley VJ, Greenwood DC, Hepworth SJ, et al. Dietary acrylamide intake and risk of breast cancer in the UK women's cohort. Br J Cancer. 103(11):1749-54, 2010.
    298. Pedersen GS, Hogervorst JG, Schouten LJ, Konings EJ, Goldbohm RA, van den Brandt PA. Dietary acrylamide intake and estrogen and progesterone receptor-defined postmenopausal breast cancer risk. Breast Cancer Res Treat. 122(1):199-210, 2010.
    299. Michels KB, Rosner BA, Chumlea WC, Colditz GA, Willett WC. Preschool diet and adult risk of breast cancer. Int J Cancer. 118(3):749-54, 2005.
    300. Knekt P, Adlercreutz H, Rissanen H, Aromaa A, Teppo L, Heliovaara M. Does antibacterial treatment for urinary tract infection contribute to the risk of breast cancer? Br J Cancer. 82:1107-10, 2000.
    301. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer. JAMA. 291:827-35, 2004.
    302. Sorensen HT, Skriver MV, Friis S, McLaughlin JK, Blot WJ, Baron JA. Use of antibiotics and risk of breast cancer: a population-based case-control study. Br J Cancer. 92:594-6, 2005.
    303. Kaye JA, Jick H. Antibiotics and the risk of breast cancer. Epidemiology. 16:688-90, 2005.
    304. Garcia Rodriguez LA, Gonzalez-Perez A. Use of antibiotics and risk of breast cancer. Am J Epidemiol. 161:616-9, 2005.
    305. Friedman GD, Oestreicher N, Chan J, Quesenberry CP Jr., Udaltsova N, Habel LA. Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women. Cancer Epidemiol Biomarkers Prev. 15(11):2102-6, 2006.
    306. Takkouche B, Regueira-Méndez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst. 100(20):1439-47, 2008.
    307. Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L. Regular aspirin use and breast cancer risk in US Black women. Cancer Causes Control. 22(11):1553-61, 2011.
    308. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13(5):518-27, 2012.
    309. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 99(8):608-15, 2007.
    310. Gierach GL, Lacey JV Jr., Schatzkin A, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res. 10(2):R38, 2008.
    311. Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. Arch Intern Med. 169(2):115-21, 2009.
    312. Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol. 30(28):3468-77, 2012.
    313. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 159(2):77-85, 2013.
    314. Ahlgren M, Melbye M, Wohlfahrt J, Sørensen TI. Growth patterns and the risk of breast cancer in women. N Engl J Med. 351(16):1619-26, 2004.
    315. Park SK, Kang D, McGlynn KA, et al. Intrauterine environments and breast cancer risk: meta-analysis and systematic review. Breast Cancer Res. 10(1):R8, 2008.
    316. Michels KB, Xue F, Terry KL, Willett WC. Longitudinal study of birthweight and the incidence of breast cancer in adulthood. Carcinogenesis. 27(12):2464-8, 2006.
    317. Tworoger SS, Eliassen AH, Missmer SA, et al. Birthweight and body size throughout life in relation to sex hormones and prolactin concentrations in premenopausal women. Cancer Epidemiol Biomarkers Prev. 15(12):2494-501, 2006.
    318. Darbre PD, Harvey PW. Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks. J Appl Toxicol. 28(5):561-78, 2008.
    319. Cosmetic Ingredient Review Expert Panel. Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products. Int J Toxicol. 27 Suppl 4:1-82, 2008.
    320. Golden R, Gandy J, Vollmer G. A review of the endocrine activity of parabens and implications for potential risks to human health. Crit Rev Toxicol. 35:435-58, 2005.
    321. Franceschi S, Favero A, La Vecchia C, et al. Body size indices and breast cancer risk before and after menopause. Int J Cancer. 67:181-6, 1996.
    322. Tavani A, Pregnolato A, La Vecchia C, Negri E, Favero A, Franceschi S. Breast size and breast cancer risk. Eur J Cancer Prev. 5:337-42, 1996.
    323. Egan KM, Newcomb PA, Titus-Ernstoff L, et al. The relation of breast size to breast cancer risk in postmenopausal women (United States). Cancer Causes Control. 10:115-8, 1999.
    324. Nagata C, Matsubara T, Fujita H, et al. Mammographic density and the risk of breast cancer in Japanese women. Br J Cancer. 92:2102-6, 2005.
    325. Kusano AS, Trichopoulos D, Terry KL, Chen WY, Willett WC, Michels KB. A prospective study of breast size and premenopausal breast cancer incidence. Int J Cancer. 118(8):2031-4, 2006.
    326. Thurfjell E, Hsieh CC, Lipworth L, Ekbom A, Adami HO, Trichopoulos D. Breast size and mammographic pattern in relation to breast cancer risk. Eur J Cancer Prev. 5:37-41,1996.
    327. Freudenheim JL, Marshall JR, Graham S, et al. Exposure to breastmilk in infancy and the risk of breast cancer. Epidemiology. 5(3):324-31, 1994.
    328. Barba M, McCann SE, Nie J, et al. Perinatal exposures and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control. 17(4):395-401, 2006.
    329. Ekbom A, Hsieh CC, Trichopoulos D, Yen YY, Petridou E, Adami HO. Breast-feeding and breast cancer in the offspring. Br J Cancer. 67(4):842-5, 1993.
    330. Weiss HA, Potischman NA, Brinton LA, et al. Prenatal and perinatal risk factors for breast cancer in young women. Epidemiology. 8(2):181-7, 1997.
    331. Titus-Ernstoff L, Egan KM, Newcomb PA, et al. Exposure to breast milk in infancy and adult breast cancer risk. J Natl Cancer Inst. 90(12):921-4, 1998.
    332. Michels KB, Trichopoulos D, Rosner BA, et al. Being breastfed in infancy and breast cancer incidence in adult life: results from the two nurses' health studies. Am J Epidemiol. 153(3):275-83, 2001.
    333. Wise LA, Titus-Ernstoff L, Newcomb PA, et al. Exposure to breast milk in infancy and risk of breast cancer. Cancer Causes Control. 20(7):1083-90, 2009.
    334. Moorman PG, Terry PD. Consumption of dairy products and the risk of breast cancer: a review of the literature. Am J Clin Nutr. 80:5-14, 2004.
    335. Ganmaa D, Sato A. The possible role of female sex hormones in milk from pregnant cows in the development of breast, ovarian and corpus uteri cancers. Med Hypotheses. 65:1028-37, 2005.
    336. Chlebowski RT, Johnson KC, Kooperberg C, et al. for the Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 100(22):1581-91, 2008.
    337. Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst. 94(17):1301-11, 2002.
    338. Pala V, Krogh V, Berrino F, et al. Meat, eggs, dairy products, and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Am J Clin Nutr. 90(3):602-12, 2009.
    339. Missmer SA, Smith-Warner SA, Spiegelman D, et al. Meat and dairy food consumption and breast cancer: a pooled analysis of cohort studies. Int J Epidemiol. 31:78-85, 2002.
    340. Dong JY, Zhang L, He K, Qin LQ. Dairy consumption and risk of breast cancer: a meta-analysis of prospective cohort studies. Breast Cancer Res Treat. 127(1):23-31, 2011.
    341. Cho E, Spiegelman D, Hunter DJ, et al. Premenopausal fat intake and risk of breast cancer. J Natl Cancer Inst. 95:1079-85, 2003.
    342. Hatch EE, Palmer JR, Titus-Ernstoff L, et al. Cancer risk in women exposed to diethylstilbestrol in utero. JAMA. 280(7):630-4, 1998.
    343. Palmer JR, Hatch EE, Rosenburg CL, et al. Risk of breast cancer in women exposed to diethylstilbestrol in utero: prelimiinary results (United States). Cancer Causes Control. 2002 Oct;13(8):753-8, 2002.
    344. Palmer JR, Wise LA, Hatch EE, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 15(8):1509-14, 2006.
    345. Troisi R, Hatch EE, Titus-Ernstoff L, et al. Cancer risk in women prenatally exposed to diethylstilbestrol. Int J Cancer. 121(2):356-60, 2007.
    346. Xue F, Michels KB. Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol. 8(12):1088-100, 2007.
    347. Verloop J, van Leeuwen FE, Helmerhorst TJ, van Boven HH, Rookus MA. Cancer risk in DES daughters. Cancer Causes Control. 21(7):999-1007, 2010.
    348. Hoover RN, Hyer M, Pfeiffer RM, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med. 365:1304-1314, 2011.
    349. Smith-Warner SA, Speigelman D, Adami HO, et al. Types of dietary fat and breast cancer: a pooled analysis of cohort studies. Int J Cancer. 92:767-774, 2001.
    350. Boyd NF, Stone J, Vogt KN, Connelly BS, Martin LJ, Minkin S. Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature. Br J Cancer. 89(9):1672-85, 2003.
    351. Kim EHJ, Willett WC, Colditz GA, et al. Dietary fat and risk of postmenopausal breast cancer in a 20-year follow-up. Am J Epidemiol. 164(10):990-7, 2006.
    352. Prentice RL, Chlebowski RT, Patterson R, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 295(6):629-42, 2006.
    353. Sieri S, Krogh V, Ferrari P, et al. Dietary fat and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 88(5):1304-12, 2008.
    354. Key TJ, Appleby PN, Cairns BJ, et al. Dietary fat and breast cancer: comparison of results from food diaries and food-frequency questionnaires in the UK Dietary Cohort Consortium. Am J Clin Nutr. 94(4):1043-52, 2011.
    355. Cho E, Spiegelman D, Hunter DJ, et al. Premenopausal fat intake and risk of breast cancer. J Natl Cancer Inst. 95:1079-85, 2003.
    356. Linos E, Willett WC, Cho E, Frazier L. Adolescent diet in relation to breast cancer risk among premenopausal women. Cancer Epidemiol Biomarkers Prev. 19(3):689-96, 2010.
    357. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 354:1586-90, 1999.
    358. Gauthier E, Paoletti X, Clavel-Chapelon F. Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. Hum Reprod. 19:2216-21, 2004.
    359. Lerner-Geva L, Keinan-Boker L, Blumstein T, et al. Infertility, ovulation induction treatments and the incidence of breast cancer--a historical prospective cohort of Israeli women. Breast Cancer Res Treat. 100(2):201-12, 2006.
    360. Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev. 16(7):1400-7, 2007.
    361. Silva Idos S, Wark PA, McCormack VA, et al. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. Br J Cancer. 100(11):1824-31, 2009.
    362. Zreik TG, Mazloom A, Chen Y, et al. Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat. 124(1):13-26, 2010.
    363. Fei C, Deroo LA, Sandler DP, Weinberg CR. Fertility drugs and young-onset breast cancer: results from the two sister study. J Natl Cancer Inst. 104(13):1021-7, 2012.
    364. Brinton LA, Trabert B, Shalev V, Lunenfeld E, Sella T, Chodick G. In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril. 99(5):1189-96, 2013.
    365. Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA. 281(17):1632-7, 1999.
    366. Feigelson HS, Jonas CR, Robertson AS, McCullough ML, Thun MJ, Calle EE. Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 12(2):161-4, 2003.
    367. Ishitani K, Lin J, Manson JE, Buring JE, Zhang SM. A prospective study of multivitamin supplement use and risk of breast cancer. Am J Epidemiol. 167(10):1197-206, 2008.
    368. Larsson SC, Bergkvist L, Wolk A. Folate intake and risk of breast cancer by estrogen and progesterone receptor status in a Swedish cohort. Cancer Epidemiol Biomarkers Prev. 17(12):3444-9, 2008.
    369. Neuhouser ML, Wassertheil-Smoller S, Thomson C, et al. Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. Arch Intern Med. 169(3):294-304, 2009.
    370. Park SY, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN. Multivitamin use and the risk of mortality and cancer incidence: the multiethnic cohort study. Am J Epidemiol. 173(8):906-14, 2011.
    371. Qin X, Cui Y, Shen L, et al. Folic acid supplementation and cancer risk: A meta-analysis of randomized controlled trials. Int J Cancer. 133(5):1033-41, 2013.
    372. Vollset SE, Clarke R, Lewington S, et al. for the B-Vitamin Treatment Trialists' Collaboration. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet. 381(9871):1029-36, 2013.
    373. Lawlor DA, Smith GD and Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control. 15:267-75, 2004.
    374. Verheus M, Peeters PH, Rinaldi S, et al. Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 119(3):659-67, 2006.
    375. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 101(1):48-60, 2009.
    376. Kabat GC, Kim M, Caan BJ, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer. 125(11):2704-10, 2009.
    377. Jonas CR, McCullough ML, Teras LF, et al. Dietary glycemic index, glycemic load, and risk of incident breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 12(6):573-7, 2003.
    378. Higginbotham S, Zhang ZF, Lee IM, et al. Dietary glycemic load and breast cancer risk in the Women's Health Study. Cancer Epidemiol Biomarkers Prev. 13(1):65-70, 2004.
    379. Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE. Dietary carbohydrates and breast cancer risk: a prospective study of the roles of overall glycemic index and glycemic load. Int J Cancer. 114(4):653-8, 2005.
    380. Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM. Dietary glycaemic index, glycaemic load and breast cancer risk: a systematic review and meta-analysis. Br J Cancer. 99(7):1170-5, 2008.
    381. Larsson SC, Bergkvist L, Wolk A. Glycemic load, glycemic index and breast cancer risk in a prospective cohort of Swedish women. Int J Cancer. 125(1):153-7, 2009.
    382. Sieri S, Pala V, Brighenti F, et al. Dietary glycemic index, glycemic load, and the risk of breast cancer in an Italian prospective cohort study. Am J Clin Nutr. 86(4):1160-6, 2007.
    383. Barclay AW, Petocz P, McMillan-Price J, et al. Glycemic index, glycemic load, and chronic disease risk--a meta-analysis of observational studies. Am J Clin Nutr. 87(3):627-37, 2008.
    384. Lajous M, Boutron-Ruault MC, Fabre A, Clavel-Chapelon F, Romieu I. Carbohydrate intake, glycemic index, glycemic load, and risk of postmenopausal breast cancer in a prospective study of French women. Am J Clin Nutr. 87(5):1384-91, 2008.
    385. Gnagnarella P, Gandini S, La Vecchia C, Maisonneuve P. Glycemic index, glycemic load, and cancer risk: a meta-analysis. Am J Clin Nutr. 87(6):1793-801, 2008.
    386. Shikany JM, Redden DT, Neuhouser ML, et al. Dietary glycemic load, glycemic index, and carbohydrate and risk of breast cancer in the Women's Health Initiative. Nutr Cancer. 63(6):899-907, 2011.
    387. Hu J, La Vecchia C, Augustin LS, et al. for the Canadian Cancer Registries Epidemiology Research Group. Glycemic index, glycemic load and cancer risk. Ann Oncol. 24(1):245-51, 2013.
    388. Romieu I, Ferrari P, Rinaldi S, et al. Dietary glycemic index and glycemic load and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr. 96(2):345-55, 2012.
    389. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 363(9418):1346-7, 2004.
    390. Rinaldi S, Peeters PH, Berrino F, et al. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 13(2):593-605, 2006.
    391. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 14(3):699-704, 2005.
    392. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 16(4):763-8, 2007.
    393. Key TJ, Appleby PN, Reeves GK, Roddam AW for the Endogenous Hormones and Breast Cancer Collaborative Group. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 11(6):530-42, 2010.
    394. Zheng W, Gustafson DR, Sinha R, et al. Well-done meat intake and the risk of breast cancer. J Natl Cancer Inst. 90:1724-9, 1998.
    395. Alexander DD, Morimoto LM, Mink PJ, Cushing CA. A review and meta-analysis of red and processed meat consumption and breast cancer. Nutr Res Rev. 23(2):349-65, 2010.
    396. Cho E, Chen WY, Hunter DJ, et al. Red meat intake and risk of breast cancer among premenopausal women. Arch Intern Med. 166(20):2253-9, 2006.
    397. Linos E, Willett WC, Cho E, Colditz G, Frazier LA. Red meat consumption during adolescence among premenopausal women and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 17(8):2146-51, 2008.
    398. Kabat GC, Cross AJ, Park Y, et al. Meat intake and meat preparation in relation to risk of postmenopausal breast cancer in the NIH-AARP diet and health study. Int J Cancer. 124(10):2430-5, 2009.
    399. Ferrucci LM, Cross AJ, Graubard BI, et al. Intake of meat, meat mutagens, and iron and the risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Br J Cancer. 101(1):178-84, 2009.
    400. Wu K, Sinha R, Holmes MD, Giovannucci E, Willett W, Cho E. Meat mutagens and breast cancer in postmenopausal women--a cohort analysis. Cancer Epidemiol Biomarkers Prev. 19(5):1301-10, 2010.
    401. Fu Z, Deming SL, Fair AM, et al. Well-done meat intake and meat-derived mutagen exposures in relation to breast cancer risk: the Nashville Breast Health Study. Breast Cancer Res Treat. 129(3):919-28, 2011.
    402. Mathes RW, Malone KE, Daling JR, et al. Migraine in postmenopausal women and the risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 17(11):3116-22, 2008.
    403. Li CI, Mathes RW, Malone KE, et al. Relationship between migraine history and breast cancer risk among premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev. 18(7):2030-4, 2009.
    404. Li CI, Mathes RW, Bluhm EC, et al. Migraine history and breast cancer risk among postmenopausal women. J Clin Oncol. 28(6):1005-10, 2010.
    405. Winter AC, Rexrode KM, Lee IM, Buring JE, Tamimi RM, Kurth T. Migraine and subsequent risk of breast cancer: a prospective cohort study. Cancer Causes Control. 24(1):81-9, 2013.
    406. Center for the Evaluation of Risks To Human Reproduction. NTP-CERHR Monograph on the potential human reproductive and development effects of bisphenol A. National Toxicology Program and U.S. Department of Health and Human Services. NIH Publication No. 08–5994. Research Triangle Park, NC. http://oehha.ca.gov/prop65/CRNR_notices/state_listing/data_callin/pdf/NTP_CERHR_0908_bisphenolA.pdf, 2008.
    407. National Toxicology Program, U.S. Department of Health and Human Services. Bisphenol A (BPA). http://www.niehs.nih.gov/health/assets/docs_a_e/bisphenol_a_bpa_508.pdf, 2010.
    408. Xue F, Willett WC, Rosner BA, Hankinson SE, Michels KB. Cigarette smoking and the incidence of breast cancer. Arch Intern Med. 171(2):125-133, 2011.
    409. Reynolds P, Hurley S, Goldberg DE, et al. Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. J Natl Cancer Inst. 96(1):29-37, 2004.
    410. U.S. Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.
    411. Pirie K, Beral V, Peto R, Roddam A, Reeves G, Green J for the Million Women Study Collaborators. Passive smoking and breast cancer in never smokers: prospective study and meta-analysis. Int J Epidemiol. 37(5):1069-79, 2008.
    412. Luo J, Margolis KL, Wactawski-Wende J, et al. Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. BMJ. 342:d1016, 2011.
    413. Johnson KC. Accumulating evidence on passive and active smoking and breast cancer risk. Int J Cancer. 117(4):619-28, 2005.
    414. Miller MD, Marty MA, Broadwin R, et al. The association between exposure to environmental tobacco smoke and breast cancer: A review by the California Environmental Protection Agency. Prev Med. Prev Med. 44(2):93-106, 2007.
    415. Hamajima N, Hirose K, Tajima K, et al. for the Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 87(11):1234-45, 2002.
    416. Al-Delaimy WK, Cho E, Chen WY, Colditz GA, Willet WC. A prospective study of smoking and risk of breast cancer in young adult women. Cancer Epidemiol Biomarkers Prev. 13(3):398-404, 2004.
    417. Gaudet MM, Gapstur SM, Sun J, Diver WR, Hannan LM, Thun MJ. Active smoking and breast cancer risk: original cohort data and meta-analysis. J Natl Cancer Inst. 105(8):515-25, 2013.
    418. Gram IT, Braaten T, Terry PD, et al. Breast cancer risk among women who start smoking as teenagers. Cancer Epidemiol Biomarkers Prev. 14:61-6, 2005.
    419. Ha M, Mabuchi K, Sigurdson AJ, et al. Smoking cigarettes before first childbirth and risk of breast cancer. Am J Epidemiol. 166(1):55-61, 2007.
    420. Bjerkaas E, Parajuli R, Weiderpass E, et al. Smoking duration before first childbirth: an emerging risk factor for breast cancer? Results from 302,865 Norwegian women. Cancer Causes Control. 24(7):1347-56, 2013.
    421. Lawlor DA, Ebrahim S, Davey Smith G. Smoking before the birth of a first child is not associated with increased risk of breast cancer: findings from the British Women's Heart and Health Cohort Study and a meta-analysis. Br J Cancer. 91(3):512-8, 2004.
    422. Ambrosone CB, Kropp S, Yang J, Yao S, Shields PG, Chang-Claude J. Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev. 17(1):15-26, 2008.
    423. Zhang J, Qiu LX, Wang ZH, Wang JL, He SS, Hu XC. NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 123(3):877-83, 2010.
    424. U.S. Department of Health and Human Services. The Health Consequences of Smoking — 50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
    425. Hsieh CY, Santell RC, Haslam SZ and Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 58:3833-8, 1998.
    426. Allred CD, Allred KF, Ju YH, et al. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 61:5045-50, 2001.
    427. Allred CD, Ju YH, Allred KF, et al. Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis. 22:1667-73, 2001.
    428. Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst. 98(7):459-71, 2006.
    429. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer. 98(1):9-14, 2008.
    430. Lee SA, Shu XO, Li H, et al. Adolescent and adult soy food intake and breast cancer risk: results from the Shanghai Women's Health Study. Am J Clin Nutr. 89(6):1920-6, 2009.
    431. Butler LM, Wu AH, Wang R, Koh WP, Yuan JM, Yu MC. A vegetable-fruit-soy dietary pattern protects against breast cancer among postmenopausal Singapore Chinese women. Am J Clin Nutr. 91(4):1013-9, 2010.
    432. Roberts FD, Newcomb PA, Trentham-Dietz A, Storer BE. Self-reported stress and risk of breast cancer. Cancer. 77:1089-93, 1996.
    433. Lillberg K, Verkasalo PK, Kaprio J, Teppo L, Helenius H, Koskenvuo M. Stress of daily activities and risk of breast cancer: a prospective cohort study in Finland. Int J Cancer. 91: 888-93, 2001.
    434. Duijts SF, Zeegers MP, Borne BV. The association between stressful life events and breast cancer risk: a meta-analysis. Int J Cancer. 107:1023-9, 2003.
    435. Lillberg K, Verkasalo PK, Kaprio J, Teppo L, Helenius H, Koskenvuo M. Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am J Epidemiol. 157:415-23, 2003.
    436. Schernhammer ES, Hankinson SE, Rosner B, et al. Job stress and breast cancer risk: the Nurses' Health Study. Am J Epidemiol. 160:1079-86, 2004.
    437. Kroenke CH, Hankinson SE, Schernhammer ES, Colditz GA, Kawachi I, Holmes MD. Caregiving stress, endogenous sex steroid hormone levels, and breast cancer incidence. Am J Epidemiol. 159:1019-27, 2004.
    438. Surtees PG, Wainwright NW, Luben RN, Khaw KT, Bingham SA. No evidence that social stress is associated with breast cancer incidence. Breast Cancer Res Treat. 120(1):169-74, 2010.
    439. Heikkilä K, Nyberg ST, Theorell T, et al. for the IPD-Work Consortium. Work stress and risk of cancer: meta-analysis of 5700 incident cancer events in 116,000 European men and women. BMJ. 346:f165, 2013.
    440. Brasky TM, Lampe JW, Potter JD, Patterson RE, White E. Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort. Cancer Epidemiol Biomarkers Prev. 19(7):1696-708, 2010.
    441. Lin J, Manson JE, Lee IM, Cook NR, Buring JE, Zhang SM. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med. 167(10):1050-9, 2007.
    442. Blackmore KM, Lesosky M, Barnett H, Raboud JM, Vieth R, Knight JA. Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol. 168(8):915-24, 2008.
    443. Engel P, Fagherazzi G, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Joint effects of dietary vitamin D and sun exposure on breast cancer risk: results from the French E3N cohort. Cancer Epidemiol Biomarkers Prev. 20(1):187-98, 2011.
    444. McCullough ML, Rodriguez C, Diver WR, et al. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 14(12):2898-904, 2005.
    445. Gissel T, Rejnmark L, Mosekilde L, Vestergaard P. Intake of vitamin D and risk of breast cancer--a meta-analysis. J Steroid Biochem Mol Biol. 111(3-5):195-9, 2008.
    446. Chlebowski RT, Johnson KC, Kooperberg C, for the Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 100(22):1581-91, 2008.
    447. Kuper H, Yang L, Sandin S, Lof M, Adami HO, Weiderpass E. Prospective study of solar exposure, dietary vitamin D intake, and risk of breast cancer among middle-aged women. Cancer Epidemiol Biomarkers Prev. 18(9):2558-61, 2009.
    448. Edvardsen K, Veierød MB, Brustad M, Braaten T, Engelsen O, Lund E. Vitamin D-effective solar UV radiation, dietary vitamin D and breast cancer risk. Int J Cancer. 128(6):1425-33, 2011.
    449. McCullough ML, Stevens VL, Patel R, et al. Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res. 11(4):R64, 2009.
    450. Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat. 121(2):469-77, 2010.
    451. Abbas S, Linseisen J, Rohrmann S, et al. Dietary intake of vitamin d and calcium and breast cancer risk in the European prospective investigation into cancer and nutrition. Nutr Cancer. 65(2):178-87, 2013.
    452. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 128(6):1414-24, 2011.
    453. Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II. Breast Cancer Res. 13(3):R50, 2011.
    454. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 155(12):827-38, 2011.
    455. Neuhouser ML, Manson JE, Millen A, et al. The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol. 175(7):673-84, 2012.
    456. Scarmo S, Afanasyeva Y, Lenner P, et al. Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study. Breast Cancer Res. 2013 Feb 26;15(1):R15. [Epub ahead of print].
    457. Kühn T, Kaaks R, Becker S, et al. Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: A nested case-control study. Int J Cancer. 133(7):1689-700, 2013.
    458. Beral V, Bull D, Doll R, et al. for the Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83 000 women with breast cancer from 16 countries. Lancet. 363:1007-16, 2004.
    459. National Cancer Institute (NCI). Summary Report: Early Reproductive Events and Breast Cancer Workshop. http://www.cancer.gov/cancerinfo/ere-workshop-report, 2003.
    460. The American College of Obstetricians and Gynecologists. Induced abortion and breast cancer risk. http://www.acog.org/Resources_And_Publications/Committee_Opinions/Committee_on_Gynecologic_Practice/Induced_Abortion_and_Breast_Cancer_Risk, 2011.
    461. National Cancer Institute. Abortion, miscarriage, and breast cancer risk. http://www.cancer.gov/cancertopics/factsheet/Risk/abortion-miscarriage, 2010.
    462. Brind J, Chinchilli VM, Severs WB and Summy-Long J. Induced abortion as an independent risk factor for breast cancer: a comprehensive review and meta-analysis. J Epidemiol Community Health. 50:481-96, 1996.
    463. Melbye M, Wohlfahrt J, Olsen JH, et al. Induced abortion and the risk of breast cancer. N Engl J Med. 336:81-5, 1997.
    464. Lazovich D, Thompson JA, Mink PJ, et al. Induced abortion and breast cancer risk. Epidemiology. 11:76-80, 2000.
    465. Paoletti X, Clavel-Chapelon F. Induced and spontaneous abortion and breast cancer risk: results from the E3N cohort study. Int J Cancer. 106(2):270-6, 2003.
    466. Palmer JR, Wise LA, Adams-Campbell LL, Rosenberg L. A prospective study of induced abortion and breast cancer in African-American women. Cancer Causes Control. 15(2):105-11, 2004.
    467. Reeves GK, Kan SW, Key T, et al. Breast cancer risk in relation to abortion: Results from the EPIC study. Int J Cancer. 119(7):1741-5, 2006.
    468. Rosenblatt KA, Gao DL, Ray RM, et al. Induced abortions and the risk of all cancers combined and site-specific cancers in Shanghai. Cancer Causes Control. 17(10):1275-80, 2006.
    469. Michels KB, Xue F, Colditz GA, Willett WC. Induced and spontaneous abortion and incidence of breast cancer among young women: a prospective cohort study. Arch Intern Med. 167(8):814-20, 2007.
    470. Henderson KD, Sullivan-Halley J, Reynolds P, et al. Incomplete pregnancy is not associated with breast cancer risk: the California Teachers Study. Contraception. 77(6):391-6, 2008.
    471. Braüner CM, Overvad K, Tjønneland A, Attermann J. Induced abortion and breast cancer among parous women: a Danish cohort study. Acta Obstet Gynecol Scand. 92(6):700-5, 2013.
    472. Helzlsouer KJ, Alberg AJ, Huang HY, et al. Serum concentrations of organochlorine compounds and the subsequent development of breast cancer. Cancer Epidemiol Biomarkers Prev. 8(6):525-32, 1999.
    473. Millikan R, De Voto E, Duell EJ, et al. Dichlorophenyldichloroethene, polychlorinated biphenyls, and breast cancer among African-American and white women in North Carolina. Cancer Epidemiol Biomarkers Prev. 9:1233-1240, 2000.
    474. Laden F, Hankinson SE, Wolff MS, et al. Plasma organochlorine levels and the risk of breast cancer: an extended follow-up in the Nurses' Health Study. Int J Cancer. 91(4):568-74, 2001.
    475. Laden F, Collman G, Iwamoto K, et al. 1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene and polychlorinated biphenyls and breast cancer: combined analysis of five U.S. studies. J Natl Cancer Inst. 93:768-76, 2001.
    476. Gammon MD, Wolff MS, Neugut AI, et al. Environmental toxins and breast cancer on Long Island. II. Organochlorine compound levels in blood. Cancer Epidemiol Biomarkers Prev. 11:686-97, 2002.
    477. Lopez-Cervantes M, Torres-Sanchez L, Tobias A, Lopez-Carrillo L. Dichlorodiphenyldichloroethane burden and breast cancer risk: a meta-analysis of the epidemiologic evidence. Environ Health Perspect. 112(2):207-14, 2004.
    478. Raaschou-Nielsen O, Pavuk M, LeBlanc A, et al. Adipose organochlorine concentrations and risk of breast cancer among postmenopausal Danish women. Cancer Epidemiol Biomarkers Prev. 14(1):67-74, 2005.
    479. Clarke CA, Glaser SL, West DW, et al. Breast cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990-1999. Breast Cancer Res. 4: R13, 2002.
    480. Hsieh CC, Trichopoulos D. Breast size, handedness and breast cancer risk. Eur J Cancer. 27:131-5, 1991.
    481. Bryant H, Brasher P. Breast implants and breast cancer—reanalysis of a linkage study. N Engl J Med. 332(23):1535-9, 1995.
    482. Hoshaw SJ, Klein PJ, Clark BD, Cook RR, Perkins LL. Breast implants and cancer: causation, delayed detection, and survival. Plast Reconstr Surg. 107(6):1393-407, 2001.
    483. McLaughlin JK, Lipworth L, Fryzek JP, et al. Long-term cancer risk among Swedish women with cosmetic breast implants: an update of a nationwide study. J Natl Cancer Inst. 98(8):557-60, 2006.
    484. Brisson J, Holowaty EJ, Villeneuve PJ, et al. Cancer incidence in a cohort of Ontario and Quebec women having bilateral breast augmentation. Int J Cancer. 118(11):2854-62, 2006.
    485. Deapen DM, Hirsch EM, Brody GS. Cancer risk among Los Angeles women with cosmetic breast implants. Plast Reconstr Surg. 119(7):1987-92, 2007.
    486. Lipworth L, Tarone RE, Friis S, et al. Cancer among Scandinavian women with cosmetic breast implants: a pooled long-term follow-up study. Int J Cancer. 124(2):490-3, 2009.
    487. Brinton LA, Brown SL, Colton T, et al. Characteristics of a population of women with breast implants compared with women seeking other types of plastic surgery. Plast Reconstr Surg. 105(3):919-27, 2000.
    488. Center for Devices and Radiological Health, U.S. Food and Drug Administration. Anaplastic large cell lymphoma (ALCL) in women with breast implants: Preliminary FDA findings and analyses. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm, 2011.
    489. Kotsopoulos J, Eliassen AH, Missmer SA, Hankinson SE, Tworoger SS. Relationship between caffeine intake and plasma sex hormone concentrations in premenopausal and postmenopausal women. Cancer. 115(12):2765-74, 2009.
    490. Ganmaa D, Willett WC, Li TY, et al. Coffee, tea, caffeine and risk of breast cancer: a 22-year follow-up. Int J Cancer. 122(9):2071-6, 2008.
    491. Ishitani K, Lin J, Manson JE, Buring JE, Zhang SM. Caffeine consumption and the risk of breast cancer in a large prospective cohort of women. Arch Intern Med. 168(18):2022-31, 2008.
    492. Boggs DA, Palmer JR, Stampfer MJ, Spiegelman D, Adams-Campbell LL, Rosenberg L. Tea and coffee intake in relation to risk of breast cancer in the Black Women's Health Study. Cancer Causes Control. 21(11):1941-8, 2010.
    493. Fagherazzi G, Touillaud MS, Boutron-Ruault MC, Clavel-Chapelon F, Romieu I. No association between coffee, tea or caffeine consumption and breast cancer risk in a prospective cohort study. Public Health Nutr. 14(7):1315-20, 2011.
    494. Gierach GL, Freedman ND, Andaya A, et al. Coffee intake and breast cancer risk in the NIH-AARP diet and health study cohort. Int J Cancer. 131(2):452-60, 2012.
    495. Li XJ, Ren ZJ, Qin JW, et al. Coffee consumption and risk of breast cancer: an up-to-date meta-analysis. PLoS One. 8(1):e52681, 2013.
    496. Jiang W, Wu Y, Jiang X. Coffee and caffeine intake and breast cancer risk: An updated dose-response meta-analysis of 37 published studies. Gynecol Oncol. 129(3):620-9, 2013.
    497. Feychting M, Ahlbom A, Kheifets L. EMF and Health. Annu Rev Public Health. 26:165-89, 2005.
    498. Moulder JE, Foster KR, Erdreich LS, McNamee JP. Mobile phones, mobile phone base stations and cancer: a review. Int J Radiat Biol. 81:189-203, 2005.
    499. Mirick DK, Davis S and Thomas DB. Antiperspirant use and the risk of breast cancer. J Natl Cancer Inst. 94:1578-80, 2002.
    500. Gikas PD, Mansfield L, Mokbel K. Do underarm cosmetics cause breast cancer? Int J Fertil Womens Med. 49:212-4, 2004.
    501. Caplan LS, Schoenfeld ER, O'Leary ES, et al. Breast cancer and electromagnetic fields—a review. Ann Epidemiol. 10:31-44, 2000.
    502. Guenel P, Raskmark P, Andersen J, et al. Incidence of cancer in persons with occupational exposure to electromagnetic fields in Denmark. Br J Industr Med. 50:758-64, 1993.
    503. Verkasalo PK, Pukkala E, Kaprio J, et al. Magnetic fields of high voltage power lines and risk of cancer in Finnish adults: Nationwide cohort study. Br Med J. 313:1047-1051, 1996.
    504. Laden F, Neas LM, Tobert PE, et al. Electric blanket usage in the Nurses' Health Study. Am J Epidemiol. 152(1):41-49, 2000.
    505. Forssén UM, Rutqvist LE, Ahlbom A, Feychting M. Occupational magnetic fields and female breast cancer: a case-control study using Swedish population registers and new exposure data. Am J Epidemiol. 161(3):250-9, 2005.
    506. Johansen C, Nielsen OR, Olsen JH, Schüz J. Risk for leukaemia and brain and breast cancer among Danish utility workers: a second follow-up. Occup Environ Med. 64(11):782-4, 2007.
    507. Chen C, Ma X, Zhong M, Yu Z. Extremely low-frequency electromagnetic fields exposure and female breast cancer risk: a meta-analysis based on 24,338 cases and 60,628 controls. Breast Cancer Res Treat. 123(2):569-76, 2010.
    508. Green A, Willett WC, Colditz GA, et al. Use of permanent hair dyes and risk of breast cancer. J Natl Cancer Inst. 79(2):253-257, 1987.
    509. Thun MJ, Altekruse SF, Namboodiri MM, et al. Hair dye use and risk of fatal cancer in U.S. women. J Natl Cancer Inst. 86(3):210-215, 1994.
    510. Mendelsohn JB, Li QZ, Ji BT, et al. Personal use of hair dye and cancer risk in a prospective cohort of Chinese women. Cancer Sci. 100(6):1088-91, 2009.
    511. Takkouche B, Etminan M, Montes-Martinez A. Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA. 293(20):2516-25, 2005.
    512. Rosenberg L, Boggs DA, Adams-Campbell LL, Palmer JR. Hair relaxers not associated with breast cancer risk: evidence from the black women's health study. Cancer Epidemiol Biomarkers Prev. 16(5):1035-7, 2007.
    513. Perkins CI, Hotes J, Kohler BA, Howe HL. Association between breast cancer laterality and tumor location, United States, 1994-1998. Cancer Causes Control. 15:637-45, 2004.
    514. Cerhan JR, Folsom AR, Potter JD, Prineas RJ. Handedness and mortality risk in older women. Am J Epidemiol. 140:368-74, 1994.
    515. Stellman SD, Wynder EL, DeRose DJ, Muscat JE. The epidemiology of left-handedness in a hospital population. Ann Epidemiol. 7:167-71, 1997.
    516. Pavia M, Hsieh CC, Ekbom A, Adami HO, Trichopoulos D. Handedness, age at menarche, and age at menopause. Obstet Gynecol. 83:579-82, 1994.
    517. Fuchs CS, Stampfer MJ, Colditz GA, et al. Alcohol consumption and mortality among women. N Engl J Med. 332(19):1245-50, 1995.
    518. Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA. 302(4):401-11, 2009.
    519. Joshipura KJ, Ascherio A, Manson JE, et al. Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA. 282(13):1233-9, 1999.
    520. Joshipura KJ, Hu FB, Manson JE, et al. The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med. 134(12):1106-14, 2001.
    521. Lichtenstein AH, Appel LJ, Brands M, et al. for the American Heart Association Nutrition Committee. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 114(1):82-96, 2006.
    522. U.S. Federal Trade Commission. Facts for consumers—At-home genetic tests: a healthy dose of skepticism may be the best prescription. www.ftc.gov/bcp/edu/pubs/consumer/health/hea02.shtm, 2006.
    523. U.S. Food and Drug Administration. Cracking down on health fraud. www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm137261.htm, 2010.
    524. Centers for Disease Control and Prevention. Genomic testing. www.cdc.gov/genomics/gtesting/index.htm, 2012.
    525. Cuzick J, Sestak I, Forbes JF, et al. on behalf of the IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 383(9922):1041-8, 2014.
    526. U.S. Food and Drug Administration. FDA Safety communication: Breast cancer screening - nipple aspirate test is not an alternative to mammography. http://www.fda.gov/medicaldevices/safety/alertsandnotices/ucm378389.htm, 2013.
    527. Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: A systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2013 Dec 24 [Epub ahead of print].  
    528. Pierce JP, Patterson RE, Senger CM, et al. Lifetime cigarette smoking and breast cancer prognosis in the after breast cancer pooling project. J Natl Cancer Inst. 106(1):djt359, 2014.
    529. Finch AP, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014 Feb 24. [Epub ahead of print].

    Updated 04/03/14 

    010673.gif

     Risk Factors & Risk Reduction Home